Similar articles for PMID: 20682975

Year	Number of Results
1991	1
1994	1
1995	1
1996	1
1997	1
1999	2
2001	2
2002	2
2003	1
2004	4
2006	2
2007	3
2008	4
2009	4
2010	10
2011	2
2012	4
2013	2
2014	1
2021	0

1

Anticancer activity of novel unnatural synthetic isoprenoids.

Adams VR, Deremer DL, Stevich B, Mattingly CA, Gallt B, Subramanian T, Troutman JM, Spielmann HP. Adams VR, et al. Anticancer Res. 2010 Jul;30(7):2505-12. Anticancer Res. 2010. PMID: 20682975

2

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J. Loboda A, et al. BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26. BMC Med Genomics. 2010. PMID: 20591134 Free PMC article.

3

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK. Ji H, et al. Cancer Res. 2007 May 15;67(10):4933-9. doi: 10.1158/0008-5472.CAN-06-4592. Cancer Res. 2007. PMID: 17510423 Free article.

4

Inhibition of farnesyl transferases from malignant and non-malignant cultured human lymphocytes by prenyl substrate analogues.

Das NP, Allen CM. Das NP, et al. Biochem Biophys Res Commun. 1991 Dec 16;181(2):729-35. doi: 10.1016/0006-291x(91)91251-7. Biochem Biophys Res Commun. 1991. PMID: 1755854

5

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. Halilovic E, et al. Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10. Cancer Res. 2010. PMID: 20699365 Free PMC article.

6

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M. Schneider CP, et al. J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa. J Thorac Oncol. 2008. PMID: 19057271 Free article. Clinical Trial.

7

Hydrophilic anilinogeranyl diphosphate prenyl analogues are Ras function inhibitors.

Roberts MJ, Troutman JM, Chehade KA, Cha HC, Kao JP, Huang X, Zhan CG, Peterson YK, Subramanian T, Kamalakkannan S, Andres DA, Spielmann HP. Roberts MJ, et al. Biochemistry. 2006 Dec 26;45(51):15862-72. doi: 10.1021/bi061704+. Epub 2006 Dec 6. Biochemistry. 2006. PMID: 17176109

8

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.

Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL. Bouali S, et al. Oncol Rep. 2009 Mar;21(3):731-5. Oncol Rep. 2009. PMID: 19212633

9

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, Waldmann H. Zimmermann G, et al. Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205. Epub 2013 May 22. Nature. 2013. PMID: 23698361

10

Effects of prenyl pyrophosphates on the binding of S-Ras proteins with KSR.

Chen CH, Fan JH, Chuang NN. Chen CH, et al. J Exp Zool. 2002 Nov 1;293(6):551-60. doi: 10.1002/jez.10165. J Exp Zool. 2002. PMID: 12410604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed